Infusion of Mesenchymal Stromal Cells can Aid Hematopoietic Recovery Following Allogeneic Hematopoietic Stem Cell Myeloablative Transplant: A Pilot Study

Meuleman, Nathalie; Tondreau, Tatiana; Ahmad, Imran; Kwan, John; Crokaert, Françoise; Delforge, Alain; Dorval, C; Martiat, Philippe; Lewalle, Philippe; Lagneaux, Laurence; Bron, Dominique

doi:10.1089/scd.2009.0029

Cited by 80 publications

(65 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A less risky procedure may be to infuse mesenchymal stromal cells, which cause much less side effects and contribute with immunomodulatory effects, especially on T-cell alloreactivity. 60 This strategy is also supported by the work of Meuleman et al 61 who, in a pilot study, were able to reverse the graft failure in a third of their patients using mesenchymal stromal cell infusions.…”

Section: Discussionmentioning

confidence: 73%

Graft failure in the modern era of allogeneic hematopoietic SCT

Olsson

Remberger

Schaffer

et al. 2012

Bone Marrow Transplant

226

165

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 73%

Graft failure in the modern era of allogeneic hematopoietic SCT

Olsson

Remberger

Schaffer

et al. 2012

Bone Marrow Transplant

226

165

View full text Add to dashboard Cite

“…They have also been used for wound healing [49,50]. In HSCT, MSCs have been successfully used to enhance engraftment and for graft failure [51][52][53][54][55]. It may be logical to use BMderived MSCs to enhance engraftment, because these cells reside in the BM and support the growth of hematopoietic cells and also produce factors of importance for hematopoiesis [27].…”

Section: Discussionmentioning

confidence: 99%

Fetal Membrane Cells for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

et al. 2013

View full text Add to dashboard Cite

The placenta protects the fetus from the mother's immune system. We have previously found that fetal membrane cells (FMCs) isolated from term placenta prevent alloreactivity in vitro. FMCs share many features with bone marrow‐derived mesenchymal stromal cells (MSCs), which we previously introduced to treat severe acute graft‐versus‐host disease (GVHD). Here, we tested FMCs for treatment of steroid‐refractory acute GVHD. After two passages in culture, approximately 109 FMCs were obtained from one single placenta, although not all cells from passage 0 and passage 1 were used for expansion. The FMCs were positive for CD29, CD44, CD73, CD90, CD105, and CD49d but were negative for hematopoietic, endothelial, and epithelial markers. Microsatellite polymorphism analysis showed that FMCs were of maternal origin. All FMCs used showed normal karyotype. Nine patients who had undergone hematopoietic stem cell transplantation (HSCT) and who had developed steroid‐refractory grade III–IV acute GVHD were given 0.9–2.8 × 106 FMCs per kg at 15 infusions. Median age was 57 years. There was no toxicity from infusion of FMCs in eight patients. One patient had seizures after infusion. Two of eight evaluable patients had a complete response and four had a partial response, giving an overall response rate of 75%. Two patients showed no response at all. Three patients are alive from 6 to 21 months after HSCT. One patient is well and two have chronic GVHD. Thus, FMCs may be successfully used for immune modulation and tissue repair. STEM CELLS2013;31:592–601

show abstract

“…6 Agents that affect MSC number or function can therefore indirectly modulate the behavior of HSCs, with implications for development and treatment of hematological malignancies. 7 Repopulation of the bone DNA damaging agents are widely used in treatment of hematogical malignancies and solid tumors. While effects on hematopoietic stem cells have been characterized, less is known about the DNA damage response in human mesenchymal stem cells (hMSCs) in the bone marrow stroma, progenitors of osteoblasts, chondrocytes and adipocytes.…”

Section: Introductionmentioning

confidence: 99%